Diaceutics PLC (LON:DXRX – Get Free Report) insider Peter Keeling sold 1,750,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of GBX 190, for a total transaction of £3,325,000.
Diaceutics Stock Down 0.5%
Shares of DXRX stock opened at GBX 194 on Monday. The firm has a market cap of £164.85 million, a PE ratio of -606.25 and a beta of 0.88. The stock has a 50 day moving average of GBX 189.12 and a 200-day moving average of GBX 160.98. Diaceutics PLC has a 12 month low of GBX 125 and a 12 month high of GBX 210. The company has a quick ratio of 9.92, a current ratio of 2.55 and a debt-to-equity ratio of 5.40.
Diaceutics (LON:DXRX – Get Free Report) last posted its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. On average, equities analysts predict that Diaceutics PLC will post 1.01 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a research note on Tuesday, November 10th. Two research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of GBX 215.
View Our Latest Report on Diaceutics
Diaceutics Company Profile
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Recommended Stories
- Five stocks we like better than Diaceutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
